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Practice Points
  UK maternal deaths secondary to hypertensive disorders of pregnancy have been 
attributed to substandard care.
  Accurate diagnosis of hypertension depends on precise blood pressure 
measurements.
  The main types of hypertensive disorders of pregnancy are: chronic, gestational and 
pre‑eclampsia (de novo or superimposed).
  All pregnant women with hypertension should be closely monitored for the development 
of pre‑eclampsia.
  Delivery before 34 weeks’ gestation should be offered if severe, refractory hypertension 
develops or documented threshold intervention values are breached.
  Birth should take place following anesthetic and neonatal consultation, and should occur 
following maternal corticosteroid administration.
  Vigilant blood pressure monitoring and antihypertensive regimen adherence is essential 
postdelivery. 
  Hypertensive control should be achieved prior to discharge.
  Hypertensive disorders in pregnancy increase the risk of maternal cardiovascular and 
renal disease in later life. All clinicians should inform their patients of these increased 
risks to ensure regular, routine monitoring.
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Hypertensive disorders of pregnancy, which 
encompass pre-existing chronic hypertension, 
gestational hypertension and pre-eclampsia, 
are the most commonly encountered medical 
complications of pregnancy worldwide. These 
disorders are estimated to affect a third of 
pregnancies in the UK and in the developing 
world, and are known to be signif icant 
contributors to annual rates of maternal and 
perinatal morbidity and mortality world-
wide [1,2]. The Eighth Report on Confidential 
Enquiries into Maternal Deaths in the UK 
produced by the Centre for Maternal and Child 
Enquiries reviewed maternal deaths recorded in 
the UK between 2006 and 2008. It identified 
hypertensive disorders (pre-eclampsia and 
eclampsia) as the second most common direct 
cause of maternal deaths, with related mortality 
rates remaining relatively static (0.83 deaths 
per 100,000 maternities [95% CI: 0.53–1.30] 
between 2006 and 2008 compared with 0.85 
deaths per 100,000 maternities [95% CI: 
0.54–1.35] between 2003 and 2005) [3]. 
Although the maternal mortality rate may 
have remained static, there is considerable 
morbidity associated with hypertensive disorders 
in pregnancy as a result of increasing rates of 
maternal comorbidities (e.g., obesity, diabetes 
and cardiovascular disease, among others) in 
the increasingly older pregnant population. 
Alarmingly, of the 22 UK maternal deaths that 
occurred between 2006 and 2008 directly related 
to pre-eclampsia, eclampsia and acute fatty liver 
of pregnancy, 20 were attributed to substandard 
clinical care, highlighting the urgent need to 
review and update the current definitions and 
clinical management of these disorders, to help 
reduce their potential catastrophic impact on the 
lives of mothers and babies affected both during 
pregnancy and in later life.
Healthy pregnancy & physiological 
changes to blood pressure
From at least 6 weeks’ gestation, maternal blood 
pressure (BP) has been found to progressively 
fall due to a reduction in systemic vascular 
resistance, thought to be secondary to vessel 
remodeling by maternal hormones [4]. From 
approximately 20 weeks’ gestation, both 
systolic and diastolic BP progressively increase 
towards term [5]. BP has been found to track 
moderately during pregnancy (i.e., women 
who started in the highest BP tertile in the first 
trimester remained in the highest tertile in the 
third trimester) [6], which has been recognized 
to be inf luenced by individual maternal 
characteristics, in particular, gestational weight 
gain, although research is required to further 
explore this relationship [7]. Postnatally, BP 
drops in the 48 h after birth, before rising back 
up to nonpregnant levels [8].
Definition of arterial hypertension in 
pregnancy
Hypertension in pregnancy is diagnosed as 
either an absolute BP rise or a relative rise above 
the recorded booking appointment BP [1]. The 
accurate diagnosis of maternal hypertension 
depends on precise BP measurements (i.e., with 
attention to cuff size, position of the arm at 
heart level and calibration of equipment) [1]. 
Conventionally, a systolic BP over 140 mmHg 
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or a diastolic BP over 90 mmHg is defined 
as hypertension in the nonpregnant adult [1]. 
However, the physiological BP changes that 
occur as the maternal cardiovascular system 
adapts to the growing fetus means it is difficult 
to use specific diagnostic BP values as standard 
across gestation [5].
BP measurement in pregnancy
To diagnose maternal hypertension, a BP 
reading should be elevated on two separate 
occasions, measured at least 4 h apart, using an 
appropriately sized BP cuff as the woman sits 
with her arm at heart level [1]. From the second 
trimester onwards, BP can be measured sitting 
or in the lateral supine position to avoid reduced 
maternal venous return by the gravid uterus 
[1]. The Korotkoff sounds used to measure BP 
should be I and V (disappearance) as opposed 
to IV (muffling), as these are more reproducible 
[9] and more accurate in determining maternal 
diastolic BP [10]. The widespread use of 
automated BP apparatus in modern obstetrics 
is controversial as this method has been found 
to systematically underestimate systolic and 
diastolic BP in both healthy and pre-eclamptic 
pregnancies by 10–20 mmHg [11]. Therefore, the 
consideration of invasive in-patient monitoring 
may be warranted in severe cases of pre-eclampsia 
[11]. In obstetric practice, 24-h ambulatory BP 
monitoring is common, but its use has not 
been fully evaluated for maternal hypertensive 
disorders. Monitoring ambulatory BP may 
minimize the prescription of antihypertensives 
for ‘white-coat hypertension’ in the clinical 
setting (estimated at 30% of pregnant women 
[12]), as well as identifying those women with 
elevated BP outside the clinical setting.
Classification of hypertensive disorders of 
pregnancy
Several different classif ication systems of 
hypertensive disorders of pregnancy exist, which 
leads to difficulty in comparing worldwide 
data on this condition. The most widely used 
definition is that of the International Society 
for the Study of Hypertension in Pregnancy 
which is, in particular, used for research and 
epidemiological purposes (Table 1) [13]. Briefly, 
the four disorders classif ied are: chronic 
hypertension, gestational hypertension, de novo 
pre-eclampsia (and its associated disorders) 
and chronic hypertension with superimposed 
pre-eclampsia. Clinically, these definitions are 
less important since all women with raised 
BP should be carefully monitored throughout 
pregnancy, especially for the associated features 
of developing pre-eclampsia.
The emphasis on the relative values of diastolic 
and systolic BP in defining hypertension has 
shifted. Classically, a severely raised diastolic BP 
(>110 mmHg) was considered more predictive of 
stroke risk. However, more recent evidence from 
an obstetric case series demonstrated that this did 
not predate stroke, whereas systolic BP did [14]. 
The importance of controlling maternal systolic 
BP reflects the evidence in the adult nonpregnant 
population where a better correlation is noted 
between the degree of systolic BP elevation, 
as opposed to diastolic BP, and the risk of 
hemorrhagic stroke (the most common type of 
stroke affecting the obstetric population) [15].
Current evidence suggests that the pattern 
of gestational BP change may distinguish 
women with essential hypertension, gestational 
hypertension and pre-eclampsia from each other 
and from normotensive women [16]. Even in early 
pregnancy, these distinct patterns may be useful 
for identifying women at risk of developing a 
hypertensive disorder later in pregnancy [16]. 
A recent study analyzed the antenatal clinic 
BP measurements (median: 14 per woman) of 
13,016 women from the Avon Longitudinal study 
of Parents and Children at different gestational 
time points (8–18, 18–30, 30–36 and ≥36 weeks’ 
gestation) and found that women who had 
essential hypertension and those who developed 
gestational hypertension or pre-eclampsia had 
higher BP at 8 weeks’ gestation (baseline) than 
normotensive women [16]. Maternal BP increased 
more rapidly from 18 weeks onward in gestational 
hypertensive and pre-eclamptic pregnancies, and 
from 30 weeks onward in essential hypertensive, 
compared with normotensive pregnancies [16]. A 
more rapid rise in BP occurring beyond 30 weeks 
of pregnancy was a risk factor for the development 
of pre-eclampsia [16]. This study suggested the 
preliminary hypothesis of a distinctive clinical 
phenotype, apparent prior to the clinical 
manifestation of these disorders, which may be 
used to identify those asymptomatic women at 
increased risk early.
Chronic hypertension
Chronic hypertension is defined as an elevated 
BP recorded at the time of booking appointment 
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or before 20 weeks’ gestation, and is either of 
primary (essential) or secondary etiology [1]. 
A prepregnancy BP is rarely documented in 
young, healthy women, therefore, the diagnosis 
of chronic hypertension may be difficult to 
make clinically if the first presentation is 
during pregnancy. If there is no prior history, 
or it has not previously been documented, 
chronic hypertension is diagnosed at the time 
of pregnancy by a persistent BP elevation 
≥140/90 mmHg prior to 20 weeks’ gestation or 
if maternal BP is elevated 6 weeks postdelivery 
[17]. Misdiagnosis may occur later in pregnancy, 
due to the physiological fall in BP prior to 
20 weeks’ gestation masking pre-existing chronic 
hypertension [4]. It is particularly important to 
exclude the rare diagnosis of pre-eclampsia in 
the second trimester.
Chronic hypertension is common in women 
at the extremes of child-bearing age and its 
prevalence is set to increase with rising maternal 
age at presentation and increasing worldwide 
prevalence of cardiovascular disease in the adult 
female population [101]. The Eighth Report on 
Confidential Enquiries into Maternal Deaths 
in the UK published in 2011 confirmed the 
increasing incidence of older mothers and 
highlighted their increased risk of pregnancy 
complications such as pre-eclampsia, gestational 
diabetes and placental abruption [3], likely to 
be due to increasing rates of metabolic and 
cardiovascular disease [101]. The rising incidence 
of maternal obesity was also noted in this report 
[3] and will likely contribute to the increasing 
rates of hypertensive disease, especially pre-
eclampsia, whose incidence risk doubles for every 
5–7 kg/m2 increase in prepregnancy BMI [18].
A secondary etiology is identified in the 
majority of cases, with underlying causes 
including: cardiovascular, renal, endocrine 
and connective tissue disease (Box  1) [19]. An 
assessment of gestational hypertensive disease is 
made on the presence of any of these secondary 
causes or known target organ damage, in 
combination with past obstetric history and the 
severity of hypertension. Chronic hypertension 
is sometimes classified in the literature as mild, 
moderate or severe (Table  1), ref lecting the 
increased risks associated with a greater degree 
of hypertension. Current evidence suggests 
that mild/moderate disease is associated with 
increased risk of placental abruption and fetal 
intrauterine growth restriction [20], although 
direct causality has not been established. 
Severe chronic hypertension prior to 20 weeks’ 
gestation has been reported, in one study, to be 
linked with a 46% increased risk of developing 
superimposed pre-eclampsia [20], with its own 
additional increased risks of maternal and fetal 
complications. Superimposed pre-eclampsia is 
diagnosed in females with chronic hypertension 
or renal disease if they develop new-onset 
proteinuria (or a sudden increase in pre-
existing proteinuria levels), or a sudden increase 
in hypertension or hemolysis, elevated liver 
enzymes and low platelet count syndrome [20].
Gestational hypertension
Gestational hypertension is estimated to 
complicate 6–7% of pregnancies in the second 
half of pregnancy [21]. The risk of superimposed 
pre-eclampsia developing is influenced by the 
gestation at which hypertension first develops. 
A diagnosis after 36 weeks of pregnancy is 
Table 1. Hypertension in pregnancy definitions.
Term Definition
Hypertension Mild 140–149/90–99 mmHg
Moderate 150–159/100–109 mmHg
Severe ≥160/≥110 mmHg
Chronic Hypertension present at the booking visit, or before 20 weeks’ 
gestation
Gestational New hypertension presenting after 20 weeks without significant 
proteinuria
Pre-eclampsia New hypertension presenting after 20 weeks’ gestation with 
proteinuria of ≥0.3 g/24 h, or ≥2+ on dipstick testing (in the absence 
of renal disease or infection)
Severe pre-eclampsia Pre-eclampsia with severe hypertension and/or with symptoms, 
and/or biochemical and/or hematological impairment
Eclampsia A convulsive condition associated with pre-eclampsia
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associated with a 10% risk of developing pre-
eclampsia [21]. An extremely uncommon cause 
of rapid hypertension is a pheochromocytoma. 
Although this is a rare cause, this diagnosis 
should be considered in a woman with the 
clinical symptoms of excessive catecholamine 
excretion (e.g., tachycardia, diaphoresis and 
sudden-onset headache) who is not responding 
to pharmacological treatment [22].
Pre-eclampsia
Pre-eclampsia is a multisystem disorder of preg-
nancy characterized by generalized endo thelial 
dysfunction, with differential organ targeting 
[23]. In the UK, the NICE Hypertension in 
Pregnancy guidelines (revised January 2011) 
define pre-eclampsia as new hypertension 
(a systolic BP ≥140 mmHg, diastolic BP 
≥90 mmHg, on repeated readings) presenting 
after 20 weeks’ gestation with signif icant 
proteinuria (≥0.3 g/24 h or 2+ on dipstick 
testing), in the absence of renal disease or 
infection [102]. Both BP and proteinuria criteria 
should be met within no more than 1 week 
of each other [17]. Eclampsia is defined as a 
generalized tonic–clonic seizure occurring on 
the background of known pre-eclampsia or as 
the presenting symptom [102].
It is estimated that pre-eclampsia complicates 
2–8% of UK pregnancies [23], affecting 
approximately 30,000 women annually [23]. The 
outcomes of these pregnancies are determined 
largely by gestational age at onset, quality of 
clinical management and the presence of pre-
existing medical disorders, with several other 
risk factors also identified (Figure  1). Adverse 
maternal and perinatal outcomes are not 
universal, indicating the wide clinical spectrum 
of this disorder. Consequently, it is often 
subclassified in the literature as either mild or 
severe disease with early or late gestational onset. 
However, these definitions can prove misleading 
with ‘mild’ pre-eclampsia developing into 
eclampsia, bypassing any severe disease signs 
and, therefore, should be used with caution in 
the clinical setting. The NICE guidance defines 
severe pre-eclampsia as either the presence of 
severe hypertension (systolic BP ≥160 mmHg, 
diastolic BP ≥110 mmHg) or mild/moderate 
hyper tension with severe proteinuria (>5 g/24 h) 
[102]. Pre-eclampsia is also considered severe if 
there is the presence of additional systemic 
complications, including: pulmonary edema, 
seizures, oliguria (<500 ml/24 h), thrombo-
cytopenia (platelets <100,000/µl), abnormal 
liver enzymes in association with persistent 
epigastric or right upper quadrant pain and 
persistent or severe CNS symptoms (e.g., altered 
mental status, headaches or blurred vision or 
blindness) [102]. Pre-eclampsia is defined as 
either early- (≤34 weeks’ gestation) or late-
onset although it is still unclear as to why 
some women develop this disorder with varied 
clinical presentations and outcomes. Current 
evidence indicates that early- and late-onset 
pre-eclampsia, with or without associated fetal 
growth restriction, are two different forms of the 
condition and, thus, are likely to have different 
etiologies [22]. Early-onset pre-eclampsia is likely 
to be due to an initial failure of placentation, 
whereas late-onset pre-eclampsia may represent 
an abnormality in the maternal physiological 
response to pregnancy [23]. The detection and 
management of early-onset pre-eclampsia, with 
its significantly higher maternal and perinatal 
Box 1. Causes of secondary chronic 
hypertension in pregnancy.
Cardiovascular
  Coarctation of aorta
  Vasculitis
Renal
  Renovascular disease
  Pre-existing renal disease
  Diabetic nephropathy
  Chronic glomerulonephritis
  Tubulointerstitial nephritis
  Chronic pyelonephritis
  Polycystic kidney disease
Endocrine
  Obesity
  Diabetes mellitus
  Hyperthyroidism
  Primary hyperaldosteronism
  Cushing's syndrome
  Pheochromocytoma
Connective tissue disease
  Systemic lupus erythematosus
  Systemic sclerosis
Others
  Cerebral sinus thrombosis
  Cerebral vasoconstriction
  Thrombotic thrombocytopenic purpura
  Hemolytic–uremic syndrome
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morbidity and mortality, is perhaps deemed 
to be of greatest importance. Annual maternal 
mortal ity is estimated at approximately 
50,000 women worldwide [24] and is often 
attributable to multisystem complications, 
such as placen tal abruption, disseminated 
intra vascular coagulopathy, hemolysis, elevated 
liver enzymes and low platelet count syndrome, 
lung/kidney/liver failure or liver/intracerebral 
hemorrhage.
Maternal cardiac disease, both acute and 
long term, is also a known complication of pre-
eclampsia/eclampsia and is currently the most 
common cause of indirect maternal death in the 
UK [3]. Fetal morbidities include intrauterine 
growth restriction, hypoxic neurological injury 
and iatrogenic prematurity, as well as perinatal 
death or chronic medical conditions associated 
with low birth weight and prematurity [3].
Although major breakthroughs have been 
made in targeting the pathophysiology of 
pre-eclampsia, the initiating event remains 
enigmatic. Pre-eclampsia is resolved by the 
delivery of the placenta and a retained placenta or 
molar pregnancy can lead to the development of 
pre-eclampsia, linking the primary defect to the 
trophoblast. This disease is believed to represent 
a failure of trophoblast invasion and adequate 
placentation. The trophoblast implantation site 
is immunologically active, and it is hypothesized 
that trophoblasts release chemokines stimulating 
immune cell recruitment and induction of a 
type 2 immune phenotype [25]. Consequently, 
poor placentation may be due to dysregulation 
of the maternal immune system [26]. The release 
of placental factors into the maternal circulation, 
secondary to placental oxidative stress and 
inflammation, may lead to widespread maternal 
endothelial and metabolic dysfunction [26], but 
these factors are yet to be fully elucidated. Recent 
work has focused on the role of maternal plasma 
markers, implicating endothelial dysfunction in 
pre-eclampsia (e.g., sFlt-1, HIF-1a and sENG), 
with expression abnormalities of these factors 
all noted in pre-eclampsia [27]. Furthermore, the 
contribution of associated maternal metabolic, 
inf lammatory and coagulation parameter 
abnormalities have also been identified in this 
condition, but with no clear causal links to its 
development [27].
The diagnosis of pre-eclampsia is made 
clinically. However, recent assessment of 
biochemical markers and associated ultrasound 
features as diagnostic predictors of pre-eclampsia 
Multiple pregnancy Nulliparity
Increased 
maternal BMI
Maternal diabetes
(Type 1, gestational)
Maternal chronic
hypertension
Hypercoagulability
Maternal smoking Maternal ethnicity
Low socio-economic status
↑ Risk of superimposed pre-eclampsia
↑ Risk of eclampsia
Past medical history of
gestational hypertension/
pre-eclampsia
Family history of
pre-eclampsia in
­rst-degree relative
Past medical history
of hypertension/
pre-eclampsia
Risk factors for hypertension
in pregnancy
Extremes of
maternal age
Further hypertensive complications:
Figure 1. Recognizable clinical risk factors for hypertension in pregnancy. 
Data taken from [1,17,21].
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have been investigated. The use of biochemical 
markers to identify high-risk pregnancies would 
allow diagnostic ultrasound assessment at a 
relatively early stage, allowing early intervention 
prior to complications. Unfortunately, the markers 
so far investigated do not appear to have a high 
enough positive predictive value to use routinely 
in clinical practice [28]. A recent systematic review 
investigated levels of circulating PlGF, VEGF, 
sFlt1 and sEng in the serum and plasma of 
pregnant women prior to 30 weeks’ gestation, but 
before clinical onset of pre-eclampsia [29]. Modest 
rises in PlGF, sFlt1 and sEng concentrations 
were all noted prior to 30 weeks’ gestation in 
women who developed pre-eclampsia, but test 
accuracies for these markers remained too poor 
for accurate prediction of pre-eclampsia in clinical 
practice [29].
The use of first or second trimester maternal 
uterine artery Doppler velocimetry has been 
extensively investigated both in isolation and 
in combination with routinely measured first 
trimester serum markers (e.g., b-hCG, PAPP-A, 
inhibin A and activin A) and maternal risk 
factor assessment [30]. A recent screening study 
for pre-eclampsia measured maternal central 
aortic systolic BP and arterial stiffness, as 
assessed by ultrasound pulse wave velocity and 
augmentation index in singleton pregnancies at 
11 + 0 to  13 + 6 weeks’ gestation and found that 
women who went on to develop pre-eclampsia 
had higher aortic systolic BP and arterial stiffness 
apparent from the first trimester of pregnancy 
[31]. One recent study using clinical, biochemical 
and ultrasound markers during the first trimester 
of pregnancy in 70 pregnant women who later 
developed pre-eclampsia and 289 control 
patients found that affected pregnancies were 
characterized by impaired placentation and an 
antiangiogenic state during the first trimester of 
pregnancy [32].
It seems likely that a multivariate screening 
model, as adopted worldwide for aneuploidy 
screening, will be the most successful in 
detecting early onset pre-eclampsia. However, 
an effective pre-eclampsia screening test is 
essentially meaningless if no effective treatment 
can be implemented that improves clinical 
outcome [33].
Treatments
Delivery of the placenta will resolve gestational 
hypertension and pre-eclampsia [1]. Therefore, 
a difficult choice often has to be made with 
regard to the correct time to intervene, so as 
to avoid both maternal systemic complications 
and neonatal iatrogenic prematurity. The short-
term treatment of chronic hypertension in 
pregnancy has its benefits in reducing rates of 
maternal cardiovascular morbidity and mortality 
[2]. However, as these women are treated for a 
≤9-month period, any short-term maternal health 
benefits should be balanced against possible short- 
and long-term consequences of antihypertensive 
therapy on fetal and neonatal health [21].
Clinical monitoring 
Women with chronic hypertension, gestational 
hypertension and those at-risk of developing 
a hypertensive disorder of pregnancy should 
be managed by a consultant obstetrician 
conservatively until 34 weeks’ gestation and 
closely monitored thereafter as close to term 
as possible (Figure 2) [102]. During this time, the 
consultant obstetrician with overall responsibility 
for care should document, on an individual basis, 
the threshold clinical and biochemical maternal 
and fetal values before 34 weeks’ gestation prior 
to considering any intervention [102].
Intrapartum care
The birth, by either induction of labor or cesarean 
section, should be based upon the clinical 
circumstances and the woman’s preference as far 
as possible. Delivery before 34 weeks’ gestation 
should be offered if a woman develops severe 
refractory hypertension or documented threshold 
maternal intervention values are breached [102]. 
Delivery at these earlier gestations will often be 
by cesarean section as an induction process is 
more likely to fail due to poor cervical ripening 
in response to prostaglandin priming [34]. Birth 
should take place following anesthetic and 
neonatal consultation and should occur following 
maternal corticosteroid administration [102].
Individual interventions
 Lifestyle
The NICE guidelines on hypertension in 
pregnancy recommend that women at risk of 
hypertensive disorders should follow the same 
advice on rest, exercise and work as that for 
healthy pregnant women [102]. Clinicians should 
reassure women with hypertension that it is safe 
to continue working and to begin or continue a 
moderate course of exercise during pregnancy [102].
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 Diet
Salt restriction is not recommended to prevent 
gestational hypertension or pre-eclampsia. 
Nutritional supplementation (e.g., magnesium, 
folic acid, vitamins C and E, fish oils, algal 
oils and garlic) is also not recommended for 
these purposes [102]. Low dietary calcium 
has been previously hypothesized to cause 
maternal hypertension, by causing negative 
feedback within the calcium homeostatic cycle, 
promoting increased vascular smooth muscle 
cell calcium and, thus, vasoconstriction. 
The most recent Cochrane systematic review 
analyzing several calcium supplementation 
trials in pregnancy found that calcium reduced 
the risk of high BP, particularly for women at 
Admit to hospital
Mild
140–149/90–99 mmHg
Moderate
150–159/100–109 mmHg
Severe
>160/>100 mmHg
Yes, until BP
<159/<109 mmHg and
monitor for new-onset
proteinuria
Treat?Treat?
Yes
First line: oral labetalol
Aim: <150/80–100 mmHg
Measure: twice weekly
Yes
First line: oral labetalol
Aim: <150/80–100 mmHg
Measure: four-times daily
Antenatal Antenatal
Yes, routinely as part of
normal antenatal monitoring
(no further bloods required 
if no further proteinuria)
Yes, at presentation
and then weekly
Intrapartum BP monitoringIntrapartum BP monitoring
Continue antenatal 
antihypertensive(s)
Continue antenatal 
antihypertensive(s)
BP measurement
Aim BP
<150/<100 mmHg
Blood
Full blood count
Kidney function and
electrolytes
Liver function tests and
bilirubin
Serum urate
Coagulation screen
Urine
Protein
Urinary
protein:creatinine ratio
Monitor BP hourly Monitor BP continuously
Figure 2. Management of hypertension in pregnancy. 
BP: Blood pressure. 
Adapted from [102].
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high risk of pre-eclampsia, as well as reducing 
serious maternal morbidity and mortality (with 
no effect on preterm delivery rates or low infant 
birth weight) [35]. However, supplementation 
has not been shown to reduce hypertension/
pre-eclampsia incidence rates in women with 
a normal calcium intake and, therefore, this 
strategy has not yet been adopted at a population 
level.
The role of antioxidant supplementation for 
the prevention of pre-eclampsia was previously 
investigated by the VIP randomized control 
trial, which found that vitamins C and E 
supplementation did not prevent pre-eclampsia 
in women at risk, but did increase the rate 
of babies born with a low birth weight [36]. 
Therefore, the routine use of antioxidants 
during pregnancy for the prevention of pre-
eclampsia and other outcomes is not supported 
[37]. However, a more recent study has found 
that maternal dietary supplementation with 
l-arginine and antioxidant vitamins together did 
reduce pre-eclampsia and eclampsia incidence 
rates in a high-risk cohort [38], indicating the 
need for further evaluation of these supplements 
combined in a low-risk population to determine 
the generalizability of this seemingly protective 
effect. However, the majority of the current, 
high-quality evidence for antioxidant use in 
pregnancy shows little or no benefit.
Pharmacological therapies during 
pregnancy
 Antihypertensive therapies
Conservative management of hypertension in 
pregnancy should be considered in all women, 
especially if presenting early in pregnancy, 
to reduce the risk of fetal hypoperfusion. 
Antihypertensive treatment is, of course, essential 
in severe hypertension to prevent maternal 
complications. A systolic BP ≥160 mmHg or 
diastolic BP ≥110 mmHg risks direct arterial 
damage, resulting in systemic complications 
such as maternal cerebral hemorrhage, cardiac 
failure and placental abruption [39]. A Cochrane 
systematic review of 46 studies trialing 
antihypertensives in mild/moderate severity 
hypertension during pregnancy (n = 3200, 
comparing treatment vs placebo) found that 
the incidence of severe hypertension was 
halved by the use of antihypertensives versus 
placebo, although no effect was noted on the 
incidence of pre-eclampsia [39]. A comparison 
of antihypertensive agents were studied in 
the same Cochrane review (n = 1282), which 
found that b-blockers appeared to be better 
than methyldopa at reducing the risk of severe 
hypertension only [39].
As there is currently no consensus regarding 
management of mild/moderate hypertension in 
pregnancy, the results of an ongoing randomized 
controlled trial, the Control of Hypertension 
in Pregnancy study, is eagerly awaited in 2013 
[103]. Pilot data from Control of Hypertension in 
Pregnancy study released in 2009 indicated an 
improved perinatal outcome in the less tightly 
controlled BP group, without a consequent 
increase in proteinuria or maternal pre-eclamptic 
end-organ complications [40]. However, these 
women developed severe hypertension more 
frequently [40], which may be associated with 
an increased risk of associated morbidities 
(e.g., hemorrhagic stroke).
The use of antihypertensives is split into 
first-, second- and third-line agents. First-line 
agents include methyldopa or an adrenoceptor 
antagonist (e.g., labetalol) [102]. Second-line 
agents include a vasodilator, often a calcium-
channel antagonist (e.g., nifedipine or 
hydralazine) [102]. Third-line treatment is the 
additional use of either an adrenoceptor agonist 
or methyldopa [102]. As can be ascertained, there 
are few antihypertensive agents available that 
have been safely trialed in pregnancy. A starting 
regimen for maternal hypertension may include 
labetalol 200 mg three-times daily, increasing 
to 300 mg four-times daily if required [102]. 
If the BP remains uncontrolled, long-acting 
calcium channel antagonists (e.g., nifedipine LA 
30–60 mg once daily) may be added [102]. If the 
BP continues to be high on the maximum doses 
of a first- and second-line agent in combination, 
then a short trial of a third-line agent may be 
attempted prior to arranging, often early, delivery 
[102]. In this case, methyldopa 0.25 g two-/three-
times daily, increasing to 1.0 g three-times daily, 
may be advocated. Unlike in the nonpregnant 
population, angiotensin-converting (ACE) 
enzyme inhibitors and angiotensin II receptor 
antagonists (ARBs) are not used during pregnancy 
for maternal hypertension management due to 
known teratogenic and fetotoxic side effects [102]. 
These drugs should be discontinued prior to 
conception and an alternative agent started [102].
As there are clear distinctions between the 
use of antihypertensives in the pregnant and 
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nonpregnant populations, the mode of action 
of several commonly used agents are detailed 
below.
Methyldopa
Methyldopa is the most extensively studied 
drug used in the pregnant population. It is a 
centrally acting a-receptor blocker and is now 
the preferred agent, over b-blockers, to manage 
chronic hypertension in pregnancy [102]. Now 
rarely used in the nonpregnant population, 
its known safety profile means it remains 
a first-line agent, with evidence suggesting 
this drug has fewer direct effects on the fetal 
vasculature than other antihypertensive agents 
[41]. However, methyldopa is associated with 
frequent side effects, including: loss of energy, 
dizziness, fatigue, depression, headache, 
vomiting and palpitations, affecting 15% of 
women in one study (although only the first 
two symptoms were signif icantly different 
between the control and treatment arms) 
[42]. The development of hemolytic anemia 
(detected by positive Coombs test) and elevated 
liver transaminases were also noted side effects. 
However, a long-term follow-up longitudinal 
trial found no long-term adverse side effects in 
the offspring [43].
Adrenoreceptor antagonists
Of the wide range of adrenoreceptor antagonists 
that exist, only labetalol, atenolol and oxprenolol 
have been studied in pregnancy [44–46]. These 
agents are often preferred clinically, especially if 
therapy is required in the third trimester, having 
better side-effect profiles than methyldopa, as 
well as appearing to be better at reducing rates of 
severe maternal hypertension [41]. They are highly 
effective, although long-term use of these agents 
has been linked to fetal intrauterine growth 
restriction [47,48]. Labetalol has comparatively 
less impact on fetal growth [46] and is therefore 
more commonly used in antenatal management 
of hypertension, with the possibility of 
conversion to atenolol in the postnatal period 
[102]. The effect on fetal growth is likely due to 
the reduction in maternal BP causing a degree 
of fetal hypoperfusion, rather than a specific 
side effect of this class of antihypertensives [47]. 
Changing to atenolol postnatally has important 
concordance implications for the new mother 
due to this drug requiring only once-daily 
dosing [49] compared with multiple daily doses 
with labetalol [49], although this may be difficult 
to initiate and monitor following hospital 
discharge. In the short term, these agents appear 
safe for the growing fetus, although the same 
safety profile information does not yet exist 
for this antihypertensive class as it does for 
methyldopa.
Calcium channel antagonists
Calcium channel antagonists act by causing 
rapid-onset vasodilation by blocking calcium 
inf lux into smooth muscle cells and are 
delivered via oral or sublingual routes. They are 
extensively used in the nonpregnant population 
and have an established use in the pregnant 
population. The NICE guidance on these 
agents suggests that there is no evidence to 
justify the clinical effectiveness of these drugs 
[102]. However, in pregnant animal models, an 
infusion of this agent has been shown to reduce 
vascular sensitivity, and in human studies has 
been shown to reduce human maternal cerebral 
artery flow velocity, which may be important 
in reducing cerebral ischemia in pre-eclampsia 
[50]. They cause no known major maternal 
or fetal side effects, but are known to cause 
several other side effects, including tachycardia, 
facial flushing, warm, sweaty peripheries and 
headache. The use of nif idepine may also 
be contraindicated if the use of magnesium 
sulfate is warranted for the treatment of 
eclamptic seizures, due to a prolongation of 
nifidipine activity causing profound maternal 
hypotension [51].
Hydralazine
Hydralazine acts by inhibiting vascular smooth 
muscle cell contraction, although the precise 
mode of action is still unknown. It is primarily 
used in the acute setting to reduce severe 
hypertension and is delivered by intramuscular 
injection or intravenous bolus/infusion [52]. It 
acts within 20–30 min, at which point it also 
induces a tachycardia (owing to its side effect 
of prolonging noradrenaline release, as well as 
the degree of hypotension achieved causing a 
baroreceptor-mediated reflex tachycardia) [52]. 
Side effects may include anxiety, restlessness and 
headache [52]. As these side effects may mimic 
the clinical presentation of severe pre-eclampsia, 
hydralazine is more commonly used as a second-
line treatment in combination with another first-
line agent, to help inhibit its sympathetic side 
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effects [52]. Current evidence does not support 
hydralazine as a first-line, sole treatment for 
severe hypertension in pregnancy, owing to 
the increased rates of maternal and neonatal 
morbidity associated with its use [52].
Thiazide diuretics
Thiazide diuretics are used infrequently in 
pregnancy. These drugs increase the risk of 
congenital abnormalities and neonatal compli-
cations [53]. Therefore, women should discuss 
other antihypertensive treatments with their 
healthcare professional if they are planning a 
pregnancy [102].
ACE inhibitors & ARBs
ACE inhibitors and ARBs should be avoided 
prior to conception and during pregnancy, 
owing to the increased risk of teratogenic and 
fetotoxic side effects [54,55]. However, it is likely 
that the elevated risks may not be specific to 
these drugs, but are instead related to maternal 
factors and diseases that typically coexist with 
hypertension in pregnancy, such as diabetes, 
advanced maternal age and obesity [56].
Magnesium sulfate
The Magpie study, published in 2002, investi-
gated the use of magnesium sulfate in the 
prevention of pre-eclampsia in at-risk women. 
The study found that its use halved the incidence 
of eclampsia in at-risk women with pre-eclampsia 
[57]. Follow-up studies looking at 2-year maternal 
outcome [58] and 18-month offspring outcome 
[59] have so far found no evidence of increased 
risk of disability or death and, therefore, this 
agent can be safely used as an anticonvulsant for 
women with pre-eclampsia at risk of developing 
eclampsia.
 Antithrombotic therapies
Aspirin
Low-dose aspirin prophylaxis has long been 
of interest because it is thought to correct 
an imbalance between the thromboxane 
A
2
:prostacyclin ratio that is associated with 
increased vasoreactivity. Women with at least 
one high risk factor or at least two moderate 
risk factors for pre-eclampsia should take 75 mg 
of aspirin daily from 12 weeks’ gestation until 
the birth of the baby to prevent recurrence [60], 
although clinical decisions should be made on 
an individual basis.
Low-molecular-weight heparin
Pre-eclampsia is related to reduced uteroplacental 
blood f low and placental thrombotic and 
inflammatory lesions. Low-molecular-weight 
heparin acts as an anticoagulant by inactivating 
thrombin and other proteases involved in 
hemostasis. An improvement in pregnancy 
outcome has been noted in women with a history 
of severe pre-eclampsia if low-molecular-weight 
heparin was administered [61]. However, so far, 
routine use of low-molecular-weight heparin as 
a preventive agent has not been implemented in 
clinical practice.
 Potential new therapies
The role of one aberrant maternal antiangiogenesis 
marker in pre-eclampsia has also been recently 
exploited for therapeutic use. A preliminary 
study investigated the extracorporeal removal 
of sFlt-1 from maternal plasma in five women 
with very preterm pre-eclampsia [62]. It found 
that extracorporeal apheresis could lower the 
elevated circulating sFlt-1, leading to reduced 
proteinuria, stabilization of maternal BP, 
without apparent adverse events to the mother 
and fetus and prolongation of pregnancy in a 
treatment frequency-dependant fashion [62]. 
This offers a potential new treatment approach 
for the pre-eclampsia spectrum.
Pharmacology after pregnancy
As highlighted, maternal BP drops in the 
immediate postpartum period, before rising 
again during the first 5 days postdelivery [63]. 
Vigilance and adherence to an antihypertensive 
regimen and BP monitoring are extremely 
important during this time period. First, 
this should avoid precipitating maternal 
hypotension with aggressive use of antenatal 
hypertensive agents and, second, avoid false 
reassurance that the woman no longer has a 
hypertensive disorder. One recent Australian 
dataset examining maternal mortality found 
the majority of eclamptic seizures to occur 
during labor (44.1%), with a substantial number 
(26.3%) occurring during the postnatal period 
(median day of postnatal seizure occurrence was 
day 4 [range: 1–55]) [64]. Therefore, midwives 
following up these women in the community 
must be aware of any antenatal hypertensive 
condition and should make appropriate 
referrals to obstetric units should postnatal BP 
or symptoms of pre-eclampsia/eclampsia occur. 
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Hypertensive control should be achieved prior 
to discharge and women with hypertension in 
pregnancy should have their BP measured daily 
for the first 2 days and at least once between 
days 3 and 5 postdelivery [102]. Should they 
require an antihypertensive at this stage, a 
b-blocker (e.g., atenolol or labetalol) is preferred 
to methyldopa due to a reported association with 
postpartum depression, although this is now 
thought to be much weaker than originally 
believed [65].
If a second agent is required, a calcium 
channel blocker or ACE inhibitor may be 
added. These medications can often be stopped 
6 weeks postpartum, at which point women with 
gestational hypertension or pre-eclampsia should 
have returned to their prepregnancy BP values 
[102]. Women with chronic hypertension can 
then resume their prepregnancy antihypertensive 
regime [102]. Should a woman choose to 
breastfeed, she should be advised that there is 
insufficient evidence on the safety profile of ACE 
inhibitors (other than enalapril or captopril), 
ARBs or amlodipine and that these drugs should 
be avoided to prevent breast milk excretion [102].
Long-term management & risk 
stratification
 Future pregnancies
Women with chronic hypertension are advised 
to seek prepregnancy counseling either in 
primary care or from a multidisciplinary team 
including consultant obstetricians and hospital 
physicians [102]. The secondary care setting 
is particularly important if the woman has 
existing comorbidities (e.g., renal disease or 
diabetes), which have caused or exacerbated 
her hypertension. Antihypertensive medication 
should be reviewed so that any ACE inhibitor 
or ARB treatment prior to conception can be 
stopped and an alternative antihypertensive 
regime commenced. Associated cardioprotective 
agents, such as statins, should also be stopped 
prior to conception [102]. These women with 
chronic hypertension should then be referred to 
consultant-led antenatal care to have increased 
antenatal BP monitoring to detect superimposed 
pre-eclampsia [102].
If a woman develops gestational hypertension, 
she has an increased risk of between 16 and 47% 
of developing it in a future pregnancy [102], and 
this should be considered in planning routine 
antenatal care. If pre-eclampsia occurs, there is 
a 16% increased risk of this condition affecting 
future pregnancies [102]. Owing to this increased 
risk, women who have developed pre-eclampsia 
in a prior pregnancy are advised to achieve and 
maintain a healthy BMI before any further 
pregnancies (although this should form part of 
prepregnancy advice for all women).
 Long-term maternal cardiovascular 
complications
There is increasing evidence to suggest that 
hyper tension in pregnancy, in particular 
pre-eclampsia, is associated with developing 
cardiovascular disease in later life [66,67]. Severe 
maternal hypertension is associated with an 
increased risk of developing ischemic heart 
disease (IHD) [68]. One population study found 
that the risk of developing IHD was higher 
in women who developed pre-eclampsia or 
eclampsia in pregnancy than in women solely 
with hypertension [69]. Another study found 
that the combination of pre-eclampsia, preterm 
delivery and low birthweight was associated with 
a sevenfold increased risk of hospital admission 
or death secondary to IHD (relative risk: 7; 
95% CI: 3.3–14.5) [70]. This increased risk was 
also found within a meta-ana lysis that reported 
that a twofold increased risk of IHD in women 
who had developed pre-eclampsia remained 
after adjusting for several other maternal 
cardiovascular risk factors (e.g., pregestational 
hypertension, diabetes, obesity and smoking) 
[71]. In particular, the timing of pre-eclampsia 
occurrence was associated with differing IHD 
risks. When pre-eclampsia occurred before 
37 weeks’ gestation, women were found to have 
an eightfold increased risk of developing IHD 
[71]. In addition, pre-eclampsia has also been 
linked with a higher risk of developing end-stage 
renal disease [72]. Pregnancy itself appears to be 
associated with an increased risk of cardiovascular 
disease. This has been hypothesized to be due 
to the pregnancy state mimicking that of the 
metabolic syndrome and its adverse effects of 
relative insulin insensitivity and dyslipidemia. 
A theory explaining this association was 
proposed by Sattar and Greer, who suggest that 
women predisposed to developing a temporary 
metabolic syndrome during pregnancy may have 
an increased propensity of developing metabolic 
and cardiovascular disease in later life [73].
This increased risk of future cardiovascular 
disease associated with a history of preeclampsia 
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has been recognized in the UK by the NICE 
Hypertension in Pregnancy guidelines, which 
advises all clinicians to inform their patients of 
these risks so as to undergo routine monitoring 
for the development of further hypertensive 
or cardiovascular disease [102]. These women 
should be encouraged, within primary care, to 
reduce their cardiovascular disease risk profile by 
maintaining a healthy weight through regular 
diet and exercise, and undergoing regular 
screening for hypertension, hyperlipidemia and 
diabetes [102]. The offspring of pre-eclampsia-
affected pregnancies also have an increased 
risk of higher BP with almost double the risk 
of stroke in later life [74]. There are therefore 
hypothetical potential effects of pre-eclampsia 
on future generations as these children go on to 
produce their own offspring.
Conclusion & future perspective
Hypertension in pregnancy remains a key topic 
that all clinicians managing pregnant women 
should remain aware of in order to prevent 
substandard care leading to maternal and 
fetal/neonatal deaths (Box  2). At present, the 
recognition of hypertensive disorders remains 
part of the routine antenatal monitoring and 
screening in the UK. In the future, it is hoped 
that the development of accurate screening 
markers will allow the early recognition of these 
high-risk pregnancies, allowing care to focus 
specifically on those women likely to encounter 
complications.
A significant future development will be 
in the identification of the causative factor(s) 
implicated in pre-eclampsia, with future 
work focusing on the differentiation between 
early- and late-onset disease in terms of etiology 
and management. A successful screening tool is 
anticipated, likely to be in the form of a serum 
or urinary marker or combination of markers, 
prior to further monitoring investigations 
(e.g., Doppler ultrasound). Systematic reviews 
have concluded that no single test fulfilling 
WHO criteria for biomarker selection can 
currently diagnose/predict pre-eclampsia, but 
this does not mean that this cannot be achieved 
in the future. If identified, the pathological 
pathway behind the predictive marker(s) may 
also serve as a therapeutic target for future 
treatments.
The recognition of adverse pregnancy outcomes 
being associated with both maternal and offspring 
long-term cardiovascular disease risk [75,76] may 
indicate the future need to employ drugs that 
protect the system in pregnancy, especially 
as increasingly more cardiovascular disease is 
diagnosed in the adult female population. A 
screening program to identify those women 
(and, potentially, children) affected by adverse 
pregnancy outcomes would allow targeted 
therapies to help reduce the current burden of 
cardiovascular disease in a timely manner.
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Box 2. Hypertensive disorders of pregnancy: summary of best practices.
  Arterial hypertension in pregnancy is defined as diastolic BP ≥90 mmHg on more than one occasion 
≥4 h apart
  The main types are: chronic, gestational and pre-eclampsia (de novo or superimposed)
  Women with chronic hypertension should have optimal BP management (including appropriate 
antihypertensive selection) prior to conception
  Methyldopa is the first-line agent for chronic hypertension and labetalol should be first-line treatment 
for pre-eclampsia
  Magnesium sulfate can be used safely as an anticonvulsant for women with pre-eclampsia at risk of 
developing eclampsia
  BP vigilance and adherence to an antihypertensive regimen are extremely important in the 
postpartum period
  ACE inhibitors, ARBs and thiazide diuretics should be avoided during pregnancy and while breast 
feeding
  Clinicians should inform patients of their increased risk of cardiovascular and renal disease in later life
ACE: Angiotensin-converting enzyme; ARB: Angiotensin II receptor antagonist; BP: Blood pressure.
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